- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04984434
Phase 1 Study of F182112 in Patients With Relapsed or Refractory Multiple Myeloma
A First-in-human, Open-label, Multiple Center Phase 1 Dose-Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetic, Immunogenicity, and Preliminary Efficacy of F182112 in Patients With Relapsed or Refractory Multiple Myeloma.
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Shandong
-
Linyi, Shandong, China, 276006
- Recruiting
- Shaohong Yin
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
1) Willing and able to provide signed and dated informed consent prior to any study-related procedures and willing and able to comply with all study procedures;
2) Male or female ≥ 18 years;
3) Patient has a history of multiple myeloma with relapsed and refractory disease, and must:
- Relapsed after an autologous stem cell transplant (ASCT), or not suitable for ASCT;
Must have received at least 2 prior multiple myeloma treatment regimens (not including autologous stem cell transplant) including a proteasome inhibitor, an immunomodulatory agent;
4) ECOG of 0-2;
5) Patients must have measurable disease, including at least one of the criteria below:
- M-protein ≥ 0.5 g/dL by SPEP/immunofixation or
- ≥ 200 mg/24 hours urine collection by UPEP or
Serum free light chain (FLC) levels > 100 mg/L (milligrams/liter involved light chain) and an abnormal kappa/lambda (κ/λ) ratio in patients without detectable serum or urine M-protein;
6) Adequate hepatic function as evidenced by meeting all the following requirements:
- Blood routine: absolute neutrophil count (ANC) ≥ 1.0×109/L, hemoglobin (Hb) ≥70g/L, Platelet ≥ 50×109/L;
- Liver function: total bilirubin ≤ 1.5 × upper limit of normal (ULN), alanine aminotransferase (ALT) ≤ 2.5 × ULN, Aspartate aminotransferase (AST) ≤ 2.5 × ULN;
Renal function: calculated creatinine clearance (CrCL) ≥ 30 mL/min (Cockroft-Gault Equation).
7) Recovery to Grade 0-1 from adverse events related to prior anticancer therapy except alopecia, ≤ Grade 2 sensory neuropathy, lymphopenia, and endocrinopathies controlled with hormone replacement therapy.
Exclusion Criteria:
1) Patient has primary light chain amyloidosis or plasma cell leukemia;
2) Patient has symptomatic central nervous system involvement of multiple myeloma;
3) Received systemic anti-myeloma therapy within 2 weeks, or received plasma exchange within 4 weeks;
4) Received any experimental drugs within 4 weeks or 5 half-lives (whichever is shorter);
5) Patient has received ≥ 40 mg/day dexamethasone equivalent within 7 days before starting F182112. Short term use of corticosteroids at doses equivalent to > 10 mg/d of prednisone;
6) Received any monoclonal antibody therapy within 30 days;
7) Prior treatment with any B cell maturation antigen (BCMA) targeted therapy;
8) Patient had a prior allogeneic stem cell transplant or had a prior autologous stem cell transplant ≤ 3 months prior to starting F182112;
9) Live virus vaccine within 30 days prior to study entry;
10) Major surgery within 4 weeks prior to study entry;
11) Concurrent malignancy within 3 years prior to entry other than adequately treated cervical carcinoma-in-situ, localized squamous cell cancer of the skin, basal cell carcinoma, prostate cancer under active surveillance, prostate cancer that has undergone definitive treatment, ductal carcinoma in situ of the breast, or ≤ T1 urothelial carcinoma;
12) Patients with active mucosa or visceral bleeding;
13) Severe cardiovascular disease, including CVA, TIA, myocardial infarction, or unstable angina within 6 months of study entry; NYHA class III or IV heart failure within 6 months of study entry; Uncontrolled arrhythmia within 6 months of study entry. Patients with a rate-controlled arrhythmia may be eligible for study entry at the discretion of the Medical Monitor;
14) Active infection requiring antibiotic, antiviral or antifungul therapy;
15) Active viral hepatitis;
16) Has a history of immunodeficiency, include HIV infection;
17) Treponema pallidum infection;
18) Received any experimental drugs or anti-tumor drugs within 2 weeks;
19) Subject has any condition that confounds the ability to interpret data from the study;
20) Females and males must practice true abstinence or agree to contraceptive methods throughout the study, and 6 months after the last giving F182112;
21) Any condition that the investigator or primary physician believes may not be appropriate for participating the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Experimental: Single Arm
|
Eight dose cohorts: 0.01, 0.1, 0.3, 1, 3, 10, 20 and 30 μg/kg) d1 treat every weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
DLTs
Time Frame: Up to 28 days
|
Incidence of dose-limiting toxicities (DLTs) from the first dose through the end of the DLT observation period
|
Up to 28 days
|
Maximum Tolerated Dose (MTD)
Time Frame: Approximately 12 months
|
Maximum Tolerated Dose
|
Approximately 12 months
|
RP2D
Time Frame: Approximately 12 months
|
Preliminary Antitumor Activity of F182112 at the RP2D(s) in Part 2
|
Approximately 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall survival (OS)
Time Frame: Approximately 24 months
|
To evaluate the duration from the first dose to death of patients with MM for any reason.
|
Approximately 24 months
|
Progression-free survival (PFS)
Time Frame: Approximately 24 months
|
Evaluation of the efficacy of F182112 in patients with MM on progression-free survival.
|
Approximately 24 months
|
Objective response rate (ORR)
Time Frame: Approximately 24 months
|
Objective remission rate was used to evaluate the efficacy of F182112 injection in patients with MM.
|
Approximately 24 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Minimal Residual Disease (MRD) Negative Rate
Time Frame: Approximately 24 months
|
Minimal Residual Disease (MRD) Negative Rate
|
Approximately 24 months
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (ANTICIPATED)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Hematologic Diseases
- Hemorrhagic Disorders
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Multiple Myeloma
- Neoplasms, Plasma Cell
Other Study ID Numbers
- NTP-F182112-001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dose-Escalation Study, Relapsed or Refractory Multiple Myeloma
-
ModernaTX, Inc.AstraZenecaActive, not recruitingDose Escalation: Relapsed/Refractory Solid Tumor Malignancies or Lymphoma | Dose Expansion: Triple Negative Breast Cancer, HNSCC, Non-Hodgkins, Urothelial Cancer, Immune Checkpoint Refractory Melanoma, and NSCLC LymphomaUnited States, Israel, Australia
-
BeBetter Med IncCompletedRelapsed or Refractory Multiple Myeloma | Relapsed or Refractory Non-Hodgkin's LymphomaChina
-
AmgenActive, not recruitingRelapsed or Refractory Multiple Myeloma | Relapsed or Refractory Acute Myeloid LeukemiaUnited States, Australia, Japan, Germany, Canada
-
Institut de Recherches Internationales ServierADIR, a Servier Group companyCompletedRelapsed or Refractory Multiple Myeloma | Relapsed or Refractory Acute Myeloid Leukemia | Relapsed or Refractory Non-Hodgkin Lymphoma | Relapsed or Refractory Chronic Lymphocytic LeukemiaUnited Kingdom, Spain, France, Australia
-
Novartis PharmaceuticalsCompletedRefractory Multiple Myeloma | Multiple Myeloma in Relapse | Relapsed and Bortezomib Refractory Multiple MyelomaUnited States
-
Oncopeptides ABTerminatedRelapsed Multiple Myeloma | Relapsed-Refractory Multiple MyelomaSerbia, Greece, Russian Federation, Czechia, Bulgaria, Georgia, Norway, Poland, Spain, Ukraine, Germany
-
Oncopeptides ABTerminatedRelapsed and/or Relapsed-refractory Multiple MyelomaUnited States, Netherlands, Denmark, Sweden, Italy
-
University of NebraskaM.D. Anderson Cancer CenterTerminatedCabozantinib as a Targeted Strategy to Reverse Carfilzomib Resistance in Refractory Multiple MyelomaMultiple Myeloma | Refractory Multiple Myeloma | Relapsed/Refractory Multiple MyelomaUnited States
-
University of LeedsCompletedRelapsed or Refractory Multiple MyelomaUnited Kingdom
-
Memorial Sloan Kettering Cancer CenterExelixisCompletedRelapsed or Refractory Multiple MyelomaUnited States